Tirzepatide (TZP), a dual GIP/GLP-1 receptor agonist, improves glycemic control and reduces body weight and the liver fat content in patients with obesity and T2D. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.